HOUSE BILL 1

E1 3lr0406 (PRE–FILED)

By: Delegates K. Kelly, Dumais, and Simmons

Requested: September 4, 2012

Introduced and read first time: January 9, 2013

Assigned to: Judiciary

AN ACT concerning

1

22

23

 $\frac{24}{25}$

26

A BILL ENTITLED

2	Criminal Law - Cannabimimetic Agents - Prohibition					
3	FOR the purpose of listing cannabimimetic agents on Schedule I to designate					
4	controlled dangerous substances that may not be legally used, possessed, or					
5	distributed; defining a certain term; and generally relating to controlled					
6	dangerous substances.					
7	BY renumbering					
8	Article – Criminal Law					
9	Section 5–101(e) through (ee), respectively					
10	to be Section 5–101(f) through (ff), respectively					
11	Annotated Code of Maryland					
12	(2012 Replacement Volume and 2012 Supplement)					
13	BY repealing and reenacting, without amendments,					
14	Article – Criminal Law					
15	Section 5–101(a)					
16	Annotated Code of Maryland					
17	(2012 Replacement Volume and 2012 Supplement)					
18	BY adding to					
19	Article – Criminal Law					
20	Section 5–101(e)					
21	Annotated Code of Maryland					

(2012 Replacement Volume and 2012 Supplement)

BY repealing and reenacting, with amendments,

Article - Criminal Law

Annotated Code of Maryland

Section 5–402(d)



1 (2012 Replacement Volume and 2012 Supplement)

- 2 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
- 3 MARYLAND, That Section(s) 5–101(e) through (ee), respectively, of Article Criminal
- 4 Law of the Annotated Code of Maryland be renumbered to be Section(s) 5–101(f)
- 5 through (ff), respectively.
- 6 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland 7 read as follows:
- 8 Article Criminal Law
- 9 5–101.
- 10 (a) In this title the following words have the meanings indicated.
- 11 (E) (1) "CANNABIMIMETIC AGENTS" MEANS SUBSTANCES THAT ARE
- 12 CANNABINOID RECEPTOR TYPE 1 (CB1 RECEPTOR) AGONISTS AS
- 13 DEMONSTRATED BY BINDING STUDIES AND FUNCTIONAL ASSAYS WITHIN ONE OF
- 14 THE FOLLOWING STRUCTURAL CLASSES:
- 15 (I) 2–(3–HYDROXYCYCLOHEXYL)PHENOL WITH
- 16 SUBSTITUTION AT THE 5-POSITION OF THE PHENOLIC RING BY ALKYL OR
- 17 ALKENYL, WHETHER OR NOT SUBSTITUTED ON THE CYCLOHEXYL RING TO ANY
- 18 EXTENT;
- 19 (II) 3-(1-NAPHTHOYL)INDOLE OR
- 20 3-(1-NAPHTHYLMETHANE)INDOLE BY SUBSTITUTION AT THE NITROGEN ATOM
- 21 OF THE INDOLE RING, WHETHER OR NOT FURTHER SUBSTITUTED ON THE
- 22 INDOLE RING TO ANY EXTENT AND WHETHER OR NOT SUBSTITUTED ON THE
- 23 NAPHTHOYL OR NAPHTHYL RING TO ANY EXTENT;
- 24 (III) 3-(1-NAPHTHOYL)PYRROLE BY SUBSTITUTION AT THE
- 25 NITROGEN ATOM OF THE PYRROLE RING, WHETHER OR NOT FURTHER
- 26 SUBSTITUTED IN THE PYRROLE RING TO ANY EXTENT AND WHETHER OR NOT
- 27 SUBSTITUTED ON THE NAPHTHOYL RING TO ANY EXTENT;
- 28 (IV) 1–(1–NAPHTHYLMETHYLENE)INDENE BY SUBSTITUTION
- 29 OF THE 3-POSITION OF THE INDENE RING, WHETHER OR NOT FURTHER
- 30 SUBSTITUTED IN THE INDENE RING TO ANY EXTENT AND WHETHER OR NOT
- 31 SUBSTITUTED ON THE NAPHTHYL RING TO ANY EXTENT; OR
- 32 (V) 3-PHENYLACETYLINDOLE OR 3-BENZOYLINDOLE BY
- 33 SUBSTITUTION AT THE NITROGEN ATOM OF THE INDOLE RING, WHETHER OR

```
NOT FURTHER SUBSTITUTED IN THE INDOLE RING TO ANY EXTENT AND
1
2
    WHETHER OR NOT SUBSTITUTED ON THE PHENYL RING TO ANY EXTENT.
3
              (2)
                   "CANNABIMIMETIC AGENTS" INCLUDES:
                        5-(1,1-DIMETHYLHEPTYL)-2-[(1R,3S)
4
                   (I)
    -3-HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497);
5
6
                        5-(1,1-DIMETHYLOCTYL)-2-[(1R,3S)
    -3-HYDROXYCYCLOHEXYL]-PHENOL
7
                                         (CANNABICYCLOHEXANOL
                                                                      OR
    CP-47,497 C8-HOMOLOG);
8
9
                   (III) 1-PENTYL-3-(1-NAPHTHOYL)INDOLE (JWH-018 AND
    AM678);
10
11
                   (IV) 1-BUTYL-3-(1-NAPHTHOYL)INDOLE (JWH-073);
                   (V)
                        1-HEXYL-3-(1-NAPHTHOYL)INDOLE (JWH-019);
12
13
                   (VI) 1-[2-(4-MORPHOLINYL)ETHYL]-3-(1-
14
    NAPHTHOYL)INDOLE (JWH-200);
                   (VII) 1-PENTYL-3-(2-METHOXYPHENYLACETYL)INDOLE
15
    (JWH-250);
16
                   (VIII)
                            1-PENTYL-3-[1-(4-METHOXYNAPHTHOYL)]INDOLE
17
18
    (JWH-081);
                        1-PENTYL-3-(4-METHYL-1-NAPHTHOYL)INDOLE
19
                   (IX)
    (JWH-122);
20
21
                   (X)
                        1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL)INDOLE
22
    (JWH-398);
                   (XI) 1–(5–FLUOROPENTYL)–3–(1–NAPHTHOYL)INDOLE
23
    (AM2201);
24
25
                   (XII) 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE
26
    (AM694);
27
                   (XIII) 1-PENTYL-3-[(4-METHOXY)-BENZOYL]INDOLE
    (SR-19 \text{ AND } RCS-4);
28
```

4

1		(XIV)	1-CYCLOHEXYLETHYL-3-(2-
2	METHOXYPHENY	LACET	YL)INDOLE (SR-18 AND RCS-8); AND
3 4	(JWH-203).	(XV)	1-PENTYL-3-(2-CHLOROPHENYLACETYL)INDOLE
5	5–402.		
6 7 8	(d) (1) the following hallu Schedule I:		terial, compound, mixture, or preparation that contains any of enic or hallucinogenic–like substances is a substance listed in
9		(i)	bufotenine;
10		(ii)	diethyltryptamine;
11		(iii)	dimethyltryptamine;
12		(iv)	4-methyl-2, 5-dimethoxyamphetamine;
13		(v)	ibogaine;
14		(vi)	lysergic acid diethylamide;
15		(vii)	marijuana;
16		(viii)	mescaline;
17		(ix)	peyote;
18		(x)	psilocybin;
19		(xi)	psilocyn;
20		(xii)	tetrahydrocannabinol;
21		(xiii)	thiophene analog of phencyclidine;
22		(xiv)	2, 5-dimethoxyamphetamine;
23		(xv)	4-bromo-2, 5-dimethoxyamphetamine;
24		(xvi)	4-methoxyamphetamine;
25		(xvii)	3, 4-methylenedioxyamphetamine;

1		(xviii) 3,	4-methylenedioxymethamphetamine (MDMA);			
2		(xix) 5-	-methoxy-3, 4-methylenedioxyamphetamine;			
3		(xx) 3,	4, 5-trimethoxyamphetamine;			
4		(xxi) N	-methyl-3-piperidyl benzilate;			
5		(xxii)	N-ethyl-3-piperidyl benzilate;			
6		(xxiii)	N-ethyl-1-phenylcyclohexylamine;			
7		(xxiv)	1–(1–phenylcyclohexyl)–pyrrolidine;			
8		(xxv)	1-(1-(2-thienyl)-cyclohexyl)-piperidine;			
9		(xxvi)	1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);			
10 11	(PEPAP);	(xxvii)	1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine			
12		(xxviii)	3, 4-methylenedioxymethcathinone (methylone);			
13		(xxix)	3, 4-methylenedioxypyrovalerone (MDPV);			
14		(xxx)	4-methylmethcathinone (mephedrone);			
15		(xxxi)	4-methoxymethcathinone (methedrone);			
16		(xxxii)	4-fluoromethcathinone (flephedrone); [and]			
17		(xxxiii)	3-fluoromethcathinone (3-FMC); AND			
18		(XXXIV)	CANNABIMIMETIC AGENTS.			
19 20 21 22	(2) Unless specifically excepted under this subtitle, a salt, isomer, or salt of an isomer of a substance listed in this subsection is a substance listed in Schedule I if the existence of the salt, isomer, or salt of an isomer is possible within the specific chemical designation.					
23 24	SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2013.					